Compliance Therapy: A Randomised Controlled Trial In Schizophrenia.
Citation:
Colin O'Donnell, Gary Donohoe, Louise Sharkey, Nicholas Owens, Raewynn Harries, Maria Migone, Anthony Kinsella, Conall Larkin, and Eadbhard O'Callaghan, Compliance Therapy: A Randomised Controlled Trial In Schizophrenia., British Medical Journal, 327, 7419, 2003, 834-838Download Item:
Abstract:
OBJECTIVE:
To evaluate the efficacy of "compliance therapy" for improving adherence to prescribed drug treatment among patients with schizophrenia.
DESIGN:
Randomised controlled trial.
SETTING:
Urban catchment area psychiatric service.
PARTICIPANTS:
94 consecutive admissions of patients with schizophrenia, 56 agreed to participate.
INTERVENTION:
Compliance therapy and non-specific counselling, each consisting of 5 sessions lasting 30-60 minutes.
MAIN OUTCOME MEASURES:
Compliance with drug treatment at one year; attitudes to treatment, symptomatology, insight, and quality of life at one year; length of "survival" in the community, bed days, and rehospitalisation rates at two years.
RESULTS:
Compliance therapy did not confer a major advantage over non-specific therapy in improving compliance at one year (43% (12/28) v 54% (15/28), difference -11% (95% confidence interval -37% to 15%) or in any of the secondary outcome measures-symptomatology, attitudes to treatment, insight, global assessment of functioning, and quality of life.
CONCLUSION:
Compliance therapy may not be of benefit to patients with schizophrenia. Attitudes to treatment at baseline predicted adherence one year later and may be a clinically useful tool.
Author's Homepage:
http://people.tcd.ie/donoghugDescription:
PUBLISHEDPMID: 14551096
Author: DONOHOE, GARY
Type of material:
Journal ArticleCollections
Series/Report no:
British Medical Journal327
7419
Availability:
Full text availableKeywords:
compliance therapyDOI:
http://dx.doi.org/10.1136/bmj.327.7419.834Metadata
Show full item recordLicences: